The indications for Prevacid include: the short-term treatment of heartburn and other symptoms of gastroesophageal reflux disease (GERD); the short-term (up to eight weeks) healing, symptom relief and maintenance of healed erosive esophagitis, a condition in which the lining of the esophagus has been damaged; the short-term (up to eight weeks) treatment of active benign gastric (stomach) ulcers; the short-term (up to four weeks) treatment of duodenal ulcer (ulcers found on the first part of the small intestine); the maintenance of healed duodenal ulcer; the long-term treatment of pathological hypersecretory conditions (which involve the overproduction of stomach acid), including Zollinger-Ellison Syndrome. Controlled studies for maintenance indications did not extend beyond 12 months. Prevacid is also indicated for the healing and risk reduction of the recurrence of gastric (stomach) ulcers associated with NSAIDs (nonsteroidal anti-inflammatory drugs) in chronic NSAID users. Controlled studies for healing did not extend beyond eight weeks and controlled studies for risk reduction of recurrence did not extend beyond twelve weeks. Symptomatic response to therapy does not preclude the presence of serious stomach problems. Prevacid is contraindicated in patients with known hypersensitivity to any component of the formulation. The most frequently reported adverse events include diarrhea (3.8%), abdominal pain (2.1%), and nausea (1.3%). For further information about Prevacid, please see the complete prescribing information below and visit www.prevacid.com. Prevpac® (lansoprazole / amoxicillin / clarithromycin), a dosing package including Prevacid, is a convenient administration option for the multi-drug regimen needed for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence. The most frequently reported side effects include diarrhea, headache, and taste perversion. Eradication of H. pylori reduces the risk of duodenal ulcer recurrence. In patients who fail this therapy, susceptibility testing should be done if possible. If clarithromycin resistance is demonstrated, a non-clarithromycin containing regimen is recommended. Clarithromycin may elevate digoxin serum concentrations. Serum digoxin levels should be carefully monitored while digoxin and clarithromycin are taken concomitantly. Prevpac is contraindicated in patients taking astemizole, cisapride, pimozide, or terfenadine; or in patients with a known hypersensitivity to any component of the formulation of Prevacid, any macrolide antibiotic or penicillin. Clarithromycin should not be used in pregnant women except in circumstances where no alternative therapy is appropriate. The dose of clarithromycin should be reduced or the dosing interval lengthened in patients with severe renal impairment. Therefore, Prevpac is not recommended in patients with creatine clearance <30 mL/min. Amoxicillin is contraindicated in patients who are allergic to penicillin. To learn more about Prevpac, please see the complete prescribing information below. Learn more about the following conditions: Prevacid Prescribing Information Prevacid® Prevpac® |
|
